trial

Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.

NCTId NCT02070211
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Unknown
Enrollment 80 (estimated)
Sponsored by Bambino Gesù Hospital and Research Institute
Primary completion 2016-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Unknown
Enrollment
80 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-06
Primary completion
2016-06
Eligibility
ALL · 12 Years · 26 Years

Interventions & indications

Drugs
omega-3 PUFAsStandard care

Sponsors

Bambino Gesù Hospital and Research InstituteLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator
OrygenCollaborator

Investigators

1
Marco Armando, MD, PhDPrincipal Investigator

Sites

1 total
Vatican City, Holy See

Linked catalysts

1
Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Pati — primary completion2016-06

Facts & assertions

4 sourced
Enrollment
80
Phase
PHASE2,PHASE3
Primary Completion Date
2016-06
Status
UNKNOWN
relationships
The graph out of here
drug
omega-3 PUFAs
drug
Standard care
drug
lead_sponsor
Bambino Gesù Hospital and Research Institute
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
Orygen
company
indication
22q11 Deletion Syndrome
indication
22q11 Deletion Syndrome
indication
Psychotic Disorders
indication
investigator
Marco Armando, MD, PhD
person